Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NextCure, Inc. NXTC
$1.72
-$0.06 (-3.52%)
На 17:31, 12 мая 2023
+248.84%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
49247722.00000000
-
week52high
5.27
-
week52low
1.16
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.06370400
-
EPS
-2.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 23 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Ladenburg Thalmann | Buy | 01 мар 2022 г. | |
| Needham | Buy | Buy | 05 ноя 2021 г. |
| Truist Securities | Buy | Hold | 05 мар 2021 г. |
| Piper Sandler | Overweight | Overweight | 04 ноя 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
| Ladenburg Thalmann | Neutral | Buy | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Feigal Ellen | A | 14250 | 14250 | 23 июн 2022 г. |
| Nicholson Garry A | A | 14250 | 14250 | 23 июн 2022 г. |
| Houston John G | A | 14250 | 14250 | 23 июн 2022 г. |
| Borgman Anne Elizabeth | A | 14250 | 14250 | 23 июн 2022 г. |
| Webster Stephen W | A | 14250 | 14250 | 23 июн 2022 г. |
| Jones Elaine V | A | 14250 | 14250 | 23 июн 2022 г. |
| Khuong Chau Quang | A | 14250 | 14250 | 23 июн 2022 г. |
| KABAKOFF DAVID S | A | 14250 | 14250 | 23 июн 2022 г. |
| Langermann Sol | A | 117400 | 117400 | 31 янв 2022 г. |
| Liu Linda | A | 65600 | 65600 | 31 янв 2022 г. |
Новостная лента
NextCure to Present at the JMP Securities Life Sciences Conference
GlobeNewsWire
09 мая 2023 г. в 07:00
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
GlobeNewsWire
11 апр 2023 г. в 07:00
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
NextCure to Present at SVB Securities Global Biopharma Conference
GlobeNewsWire
07 февр 2023 г. в 07:00
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
NextCure to Present at Upcoming Investor Conferences
GlobeNewsWire
22 ноя 2022 г. в 08:00
BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the following investor conferences:
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire
03 ноя 2022 г. в 09:15
BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans. NC525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and is being developed for the treatment of advanced myeloid leukemia (AML).